What one share of Foghorn Therapeutics holds
Foghorn is a clinical stage, precision therapeutics biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system, an untapped opportunity for therapeutic intervention in oncology and with potential in a wide spectrum of other diseases, including immunology and inflammation.
Foghorn Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.55 |
|---|---|
| Profit | −$0.97 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$1.27 |
| Cash and investments | $1.16 |
| Book value | −$1.38 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$12.20 | $0.23 | −$11.28 | — | — |
| 2020 | $0.04 | −$6.23 | $1.46 | −$4.30 | — | — |
| 2021 | $0.04 | −$2.73 | $0.09 | −$1.44 | — | — |
| 2022 | $0.46 | −$2.62 | $0.03 | $4.63 | — | $0.00 |
| 2023 | $0.81 | −$2.34 | $0.03 | −$2.84 | — | −$1.83 |
| 2024 | $0.41 | −$1.58 | $0.02 | −$1.85 | — | −$0.82 |
| 2025 | $0.49 | −$1.18 | $0.00 | −$1.37 | — | −$1.92 |
Common questions about Foghorn Therapeutics
How much does one share of Foghorn Therapeutics earn?
Over the last 12 months, Foghorn Therapeutics lost $0.97 for each share on $0.55 of sales.
Does Foghorn Therapeutics pay a dividend?
Foghorn Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Foghorn Therapeutics’s book value per share?
Foghorn Therapeutics’s book value is negative (−$1.38 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of Foghorn Therapeutics have?
Each share of Foghorn Therapeutics has $1.16 of cash and investments, as of June 30, 2026.
What is Foghorn Therapeutics’s free cash flow per share?
−$1.27 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Foghorn Therapeutics bought back shares?
Foghorn Therapeutics’s share count rose about 1402% from 2019 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.